Drug Trial Radar · NCT06845202
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
105
Actual
Start
Mar 3, 2025
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Feb 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
Conditions
- Obese or Overweight Healthy Volunteers
- Type 2 Diabetes Mellitus (T2DM)
Interventions
ALN-4324Drug
ALN-4324 will be administered subcutaneously (SC)
PlaceboDrug
Placebo will be administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Frequency of Adverse Events (AEs)Time frame: Up to 9 months
- Part B: Frequency of Adverse EventsTime frame: Up to 12 months
Locations
22 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Montclair, California
Clinical Trial Site
Washington D.C., District of Columbia
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Marlton, New Jersey
Clinical Trial Site
Monroe, North Carolina
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
San Miguel de Tucumán, Argentina
Clinical Trial Site
Concord, Canada
Clinical Trial Site
Mount Royal, Canada
Clinical Trial Site
Vancouver, Canada
Clinical Trial Site
Santiago, Chile
Clinical Trial Site
Santiago, Chile
Clinical Trial Site
Santiago, Chile
Clinical Trial Site
Essen, Germany
Clinical Trial Site
Gdansk, Poland
Clinical Trial Site
Tarnów, Poland
Clinical Trial Site
Warsaw, Poland
Clinical Trial Site
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.